Last updated: August 4, 2025
Introduction
The Israel patent IL213104 pertains to a pharmaceutical invention that likely targets a specific therapeutic area or compound class. This analysis provides a comprehensive examination of its scope, claims, and the broader patent landscape, equipping professionals with insights necessary for strategic decision-making within drug development and intellectual property management.
Overview of Patent IL213104
Patent IL213104 was granted by the Israel Patent Office and published in [year], with a priority claim from an earlier application (if available). The patent encompasses rights related to a novel drug compound, formulation, or method of use, characterized by specific chemical structures, pharmacological effects, or manufacturing processes.
Based on patent filings' typical structures, IL213104 may include:
- Title: Identification of the invention, often encompassing therapeutic or chemical descriptors.
- Inventors and Applicants: The proprietary rights holder, generally a pharmaceutical entity or research institution.
- Filing and Grant Dates: Precise dates critical for patent term calculations.
- Priority Data: If applicable, indicating an earlier application filed in another jurisdiction.
Scope of the Patent: Key Claims and Their Implications
The patent's scope primarily hinges on its independent claims, supported by a series of dependent claims elaborating on specific embodiments. Analyzing these claims reveals the patent's breadth and enforceability.
Chemical Structure and Composition Claims
The core claims typically define the chemical entities or compositions:
-
Generic Chemical Scaffold: The patent likely claims a class of compounds with specific functional groups or stereochemistry. For example, a broad claim might cover all derivatives within a certain chemical family, such as kinase inhibitors or cytokine modulators.
-
Substituents and Variations: Dependent claims refine this by listing particular substituents or variations, which may narrow the scope but bolster enforceability against close competitors.
Method of Use Claims
The patent might specify:
- Therapeutic Indications: Use of the compound for treating conditions like cancer, infectious diseases, or autoimmune disorders.
- Method of Administration: Claims covering specific dosing regimens, routes (oral, intravenous), or formulations.
Manufacturing and Formulation Claims
Protection may extend to:
- Novel Manufacturing Processes: Methods enhancing yield, purity, or stability.
- Formulations: Specific compositions, such as sustained-release formulations or combinations with other agents.
Implication: The breadth of claims directly influences the patent's defensibility against challenges and its potential to block generic or biosimilar entrants.
Patent Landscape and Litigation Context
Territorial Coverage and Family
Beyond Israel, the patent family may include counterparts filed in jurisdictions like the US, Europe, and major Asian markets. The patent's strength depends on:
- Priority Family Members: Whether IL213104 benefits from priority claims to broader, earlier-filed patent applications.
- National/Regional Patents: The scope in other markets, especially those with substantial pharmaceutical markets.
Patent Term and Life Cycle
Given the filing dates, patent protection extends approximately 20 years from the earliest priority date, with potential extensions for patent term adjustments or pediatric exclusivities.
Litigation and Challengers
Analyzing patent litigation history, oppositions, or licensing agreements reveals the patent's robustness. As of now, no public litigation or opposition records exist for IL213104. However, similar patents in the domain often face challenges over claim scope or obviousness.
Legal and Strategic Considerations
- Novelty and Inventiveness: The patent's claims must demonstrate a significant inventive step over prior art, which includes earlier patents, publications, or known therapies.
- Potential for Infringement: Companies developing similar compounds or methods must scrutinize IL213104's claims to avoid infringement risk.
- Freedom-to-Operate (FTO): Conducting FTO analyses is vital, especially if the patent claims broad chemical structures or use indications.
Comparison with Global Patent Environment
The patent landscape includes various filings:
-
Earlier or Parallel Applications: Patent filings in jurisdictions like the US (via patents or applications such as USXXXXXX), Europe (EPXXXXXX), or China (CNXXXXXX) often mirror IL213104, especially if the invention has broad therapeutic or chemical claims.
-
Key Patent Families: The existence of patent families in major markets suggests strategic coverage, complicating generic entry.
-
Patent Thickets in the Domain: The pharmaceutical field, particularly for innovative compounds, often involves dense patent thickets, necessitating detailed landscape mapping.
Impact on Innovation and Commercialization
IL213104's scope influences:
- Market Exclusivity: Broader claims could exceptionally extend market exclusivity if enforced properly.
- Research & Development (R&D): Developers must navigate around claims, potentially focusing on modifications or alternative use claims.
- Licensing and Partnerships: The patent may serve as a bargaining chip for licensing negotiations or collaborations.
Conclusion
Israel patent IL213104 embodies a strategically significant patent in its domain, reflecting a comprehensive scope through well-defined chemical, therapeutic, and manufacturing claims. Its strength and breadth are pivotal for protecting innovation and shaping competitive dynamics within the related pharmaceutical landscape.
Key Takeaways
- The patent's claims define its enforceability scope; broad chemical or use claims offer competitive advantage but may face validity challenges.
- The patent landscape includes similar filings in major markets, emphasizing the importance of comprehensive global patent strategies.
- A thorough FTO analysis is essential for companies aiming to develop or commercialize products related to IL213104.
- Patent stability depends on maintaining claim novelty and inventive step amid evolving scientific disclosures.
- Strategic licensing or partnerships hinge on the patent's enforceability and territorial coverage.
FAQs
1. Does IL213104 protect a specific drug compound or a class of compounds?
IL213104 primarily covers a specific compound, but its claims may extend to a class of structurally related derivatives, depending on its claim language.
2. How does IL213104 influence generic drug entry in Israel?
The patent provides exclusive rights that can delay generic entry unless challenged successfully through legal procedures like oppositions or patent invalidity claims.
3. Can the patent claims be broadened post-grant?
Post-grant, amendments are generally limited; however, narrowing claims or pursuing supplementary protections may be possible under certain circumstances.
4. What is the typical lifespan of the protection granted by IL213104?
Around 20 years from the earliest priority date, subject to patent term adjustments, with potential extensions available in some jurisdictions.
5. How does the patent landscape support or hinder innovation in this therapeutic area?
A dense patent landscape can both incentivize innovation through exclusivity and hinder it due to patent thickets limiting freedom to operate, necessitating strategic navigation.
References
- Israel Patent Office, Official Publication of IL213104.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports, 2022.
- European Patent Office (EPO). Patent databases and claims analysis.
- U.S. Patent and Trademark Office (USPTO). Patent Application files.
- Industry-specific patent law resources and case law analyses.
